Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NATR's Cash to Debt is ranked higher than
97% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. NATR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NATR' s 10-Year Cash to Debt Range
Min: 1.41  Med: 21.12 Max: No Debt
Current: No Debt
Equity to Asset 0.66
NATR's Equity to Asset is ranked higher than
55% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NATR: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
NATR' s 10-Year Equity to Asset Range
Min: 0.31  Med: 0.63 Max: 0.73
Current: 0.66
0.31
0.73
Interest Coverage No Debt
NATR's Interest Coverage is ranked higher than
96% of the 389 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2854.00 vs. NATR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NATR' s 10-Year Interest Coverage Range
Min: 13.14  Med: 199.66 Max: 9999.99
Current: No Debt
13.14
9999.99
F-Score: 4
Z-Score: 4.56
M-Score: -2.67
WACC vs ROIC
4.91%
17.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 4.27
NATR's Operating margin (%) is ranked lower than
59% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. NATR: 4.27 )
Ranked among companies with meaningful Operating margin (%) only.
NATR' s 10-Year Operating margin (%) Range
Min: 0.83  Med: 5.93 Max: 11.97
Current: 4.27
0.83
11.97
Net-margin (%) 1.57
NATR's Net-margin (%) is ranked lower than
66% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.89 vs. NATR: 1.57 )
Ranked among companies with meaningful Net-margin (%) only.
NATR' s 10-Year Net-margin (%) Range
Min: -2.25  Med: 4.78 Max: 7.72
Current: 1.57
-2.25
7.72
ROE (%) 4.21
NATR's ROE (%) is ranked lower than
57% of the 696 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. NATR: 4.21 )
Ranked among companies with meaningful ROE (%) only.
NATR' s 10-Year ROE (%) Range
Min: -12.81  Med: 15.94 Max: 33.07
Current: 4.21
-12.81
33.07
ROA (%) 2.65
NATR's ROA (%) is ranked lower than
53% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.32 vs. NATR: 2.65 )
Ranked among companies with meaningful ROA (%) only.
NATR' s 10-Year ROA (%) Range
Min: -5.25  Med: 8.95 Max: 23.36
Current: 2.65
-5.25
23.36
ROC (Joel Greenblatt) (%) 25.04
NATR's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. NATR: 25.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NATR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 15.41  Med: 55.30 Max: 159.65
Current: 25.04
15.41
159.65
Revenue Growth (3Y)(%) -4.00
NATR's Revenue Growth (3Y)(%) is ranked lower than
78% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. NATR: -4.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NATR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4  Med: 2.00 Max: 14.1
Current: -4
-4
14.1
EBITDA Growth (3Y)(%) -7.40
NATR's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 492 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. NATR: -7.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NATR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -27.5  Med: 1.00 Max: 30
Current: -7.4
-27.5
30
» NATR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

NATR Guru Trades in Q3 2014

Chuck Royce 1,700 sh (New)
Jim Simons 156,800 sh (+12.24%)
» More
Q4 2014

NATR Guru Trades in Q4 2014

Jim Simons 181,500 sh (+15.75%)
Chuck Royce 1,700 sh (unchged)
» More
Q1 2015

NATR Guru Trades in Q1 2015

Jim Simons 209,700 sh (+15.54%)
Chuck Royce 1,700 sh (unchged)
» More
Q2 2015

NATR Guru Trades in Q2 2015

Jim Simons 245,500 sh (+17.07%)
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NATR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 41.46
NATR's P/E(ttm) is ranked lower than
65% of the 479 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.40 vs. NATR: 41.46 )
Ranked among companies with meaningful P/E(ttm) only.
NATR' s 10-Year P/E(ttm) Range
Min: 7.88  Med: 16.75 Max: 159.88
Current: 41.46
7.88
159.88
Forward P/E 13.40
NATR's Forward P/E is ranked higher than
81% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.58 vs. NATR: 13.40 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 67.90
NATR's PE(NRI) is ranked lower than
77% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.40 vs. NATR: 67.90 )
Ranked among companies with meaningful PE(NRI) only.
NATR' s 10-Year PE(NRI) Range
Min: 7.89  Med: 15.25 Max: 87
Current: 67.9
7.89
87
P/B 1.72
NATR's P/B is ranked higher than
70% of the 644 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. NATR: 1.72 )
Ranked among companies with meaningful P/B only.
NATR' s 10-Year P/B Range
Min: 1.43  Med: 2.22 Max: 3.87
Current: 1.72
1.43
3.87
P/S 0.65
NATR's P/S is ranked higher than
87% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.13 vs. NATR: 0.65 )
Ranked among companies with meaningful P/S only.
NATR' s 10-Year P/S Range
Min: 0.21  Med: 0.65 Max: 1.96
Current: 0.65
0.21
1.96
POCF 23.87
NATR's POCF is ranked higher than
51% of the 387 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.20 vs. NATR: 23.87 )
Ranked among companies with meaningful POCF only.
NATR' s 10-Year POCF Range
Min: 6.3  Med: 11.08 Max: 150.08
Current: 23.87
6.3
150.08
EV-to-EBIT 11.73
NATR's EV-to-EBIT is ranked higher than
75% of the 488 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.19 vs. NATR: 11.73 )
Ranked among companies with meaningful EV-to-EBIT only.
NATR' s 10-Year EV-to-EBIT Range
Min: 3.5  Med: 10.10 Max: 136.6
Current: 11.73
3.5
136.6
PEG 10.78
NATR's PEG is ranked lower than
80% of the 257 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.57 vs. NATR: 10.78 )
Ranked among companies with meaningful PEG only.
NATR' s 10-Year PEG Range
Min: 0.22  Med: 0.41 Max: 24.63
Current: 10.78
0.22
24.63
Shiller P/E 13.06
NATR's Shiller P/E is ranked higher than
86% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.90 vs. NATR: 13.06 )
Ranked among companies with meaningful Shiller P/E only.
NATR' s 10-Year Shiller P/E Range
Min: 11.33  Med: 22.67 Max: 200.11
Current: 13.06
11.33
200.11
Current Ratio 2.08
NATR's Current Ratio is ranked lower than
55% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. NATR: 2.08 )
Ranked among companies with meaningful Current Ratio only.
NATR' s 10-Year Current Ratio Range
Min: 1.32  Med: 2.08 Max: 2.48
Current: 2.08
1.32
2.48
Quick Ratio 1.33
NATR's Quick Ratio is ranked lower than
62% of the 617 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. NATR: 1.33 )
Ranked among companies with meaningful Quick Ratio only.
NATR' s 10-Year Quick Ratio Range
Min: 0.83  Med: 1.31 Max: 1.79
Current: 1.33
0.83
1.79
Days Inventory 169.77
NATR's Days Inventory is ranked lower than
75% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.66 vs. NATR: 169.77 )
Ranked among companies with meaningful Days Inventory only.
NATR' s 10-Year Days Inventory Range
Min: 157.14  Med: 184.10 Max: 213.58
Current: 169.77
157.14
213.58
Days Sales Outstanding 7.43
NATR's Days Sales Outstanding is ranked higher than
95% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.39 vs. NATR: 7.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
NATR' s 10-Year Days Sales Outstanding Range
Min: 6.2  Med: 8.71 Max: 11.98
Current: 7.43
6.2
11.98

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.40
NATR's Dividend Yield is ranked higher than
83% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.41 vs. NATR: 3.40 )
Ranked among companies with meaningful Dividend Yield only.
NATR' s 10-Year Dividend Yield Range
Min: 0.3  Med: 1.78 Max: 4.04
Current: 3.4
0.3
4.04
Dividend Payout 0.58
NATR's Dividend Payout is ranked lower than
73% of the 396 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. NATR: 0.58 )
Ranked among companies with meaningful Dividend Payout only.
NATR' s 10-Year Dividend Payout Range
Min: 0.1  Med: 0.16 Max: 1.67
Current: 0.58
0.1
1.67
Yield on cost (5-Year) 3.33
NATR's Yield on cost (5-Year) is ranked higher than
75% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. NATR: 3.33 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NATR' s 10-Year Yield on cost (5-Year) Range
Min: 0.3  Med: 1.78 Max: 4.04
Current: 3.33
0.3
4.04
Share Buyback Rate -4.00
NATR's Share Buyback Rate is ranked lower than
56% of the 459 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -3.00 vs. NATR: -4.00 )
Ranked among companies with meaningful Share Buyback Rate only.
NATR' s 10-Year Share Buyback Rate Range
Min: 5.5  Med: 0.00 Max: -4
Current: -4

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 5.12
NATR's Price/Net Current Asset Value is ranked higher than
63% of the 385 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. NATR: 5.12 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NATR' s 10-Year Price/Net Current Asset Value Range
Min: 2.84  Med: 5.58 Max: 118.75
Current: 5.12
2.84
118.75
Price/Tangible Book 1.74
NATR's Price/Tangible Book is ranked higher than
73% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. NATR: 1.74 )
Ranked among companies with meaningful Price/Tangible Book only.
NATR' s 10-Year Price/Tangible Book Range
Min: 1.48  Med: 2.33 Max: 10.64
Current: 1.74
1.48
10.64
Price/Projected FCF 1.43
NATR's Price/Projected FCF is ranked higher than
72% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. NATR: 1.43 )
Ranked among companies with meaningful Price/Projected FCF only.
NATR' s 10-Year Price/Projected FCF Range
Min: 0.42  Med: 1.10 Max: 2.09
Current: 1.43
0.42
2.09
Price/Median PS Value 1.03
NATR's Price/Median PS Value is ranked higher than
63% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.28 vs. NATR: 1.03 )
Ranked among companies with meaningful Price/Median PS Value only.
NATR' s 10-Year Price/Median PS Value Range
Min: 0.36  Med: 1.02 Max: 3.47
Current: 1.03
0.36
3.47
Price/Graham Number 1.14
NATR's Price/Graham Number is ranked higher than
77% of the 367 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. NATR: 1.14 )
Ranked among companies with meaningful Price/Graham Number only.
NATR' s 10-Year Price/Graham Number Range
Min: 0.66  Med: 1.27 Max: 3.58
Current: 1.14
0.66
3.58
Earnings Yield (Greenblatt) (%) 8.48
NATR's Earnings Yield (Greenblatt) (%) is ranked higher than
82% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. NATR: 8.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NATR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.7  Med: 9.90 Max: 28.5
Current: 8.48
0.7
28.5
Forward Rate of Return (Yacktman) (%) 0.94
NATR's Forward Rate of Return (Yacktman) (%) is ranked lower than
64% of the 315 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.18 vs. NATR: 0.94 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NATR' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -12.6  Med: 3.10 Max: 40.8
Current: 0.94
-12.6
40.8

Analyst Estimate

Dec15
Revenue(Mil) 394
EPS($) 0.97
EPS without NRI($) 0.97

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:LRLCY, KMB, RBGPY, EL, UNLRY » details
Natures Sunshine Products Inc, was founded in 1972 and incorporated in Utah in 1976. The Company together with its subsidiaries is a natural health and wellness company engaged in the manufacturing and direct selling of nutritional and personal care products. The Company sells its products to a sales force of independent Managers and Distributors who use the products themselves or resell them to other distributors or customers. The Company has two reportable business segments that operate under the Nature's Sunshine Products brand and are divided based on their geographic operations in the United States and in countries outside the United States. The Company's third reportable business segment operates under the Synergy brand, which offers marketing plans, Distributor compensation plans and product formulations that are sufficiently different from those of NSP United States and NSP International to warrant accounting for these operations as a separate business segment. The Company has line of over 700 products includes several different product classifications, such as immunity, cardiovascular, digestive, personal care, weight management as well as other general health products. It purchase herbs and other raw materials in bulk and, after quality control testing, it formulate, encapsulate, tablet or concentrate them, and package them for shipment. Its products are manufactured at its facility in Spanish Fork, Utah. Contract manufacturers produce some of its vitamins, mineral and other nutritional supplements, personal care products and certain other miscellaneous products in accordance with its specifications and standards. The Company's independent Distributors market its products to customers through direct-selling techniques, as well as sponsoring other Distributors. Its products sold in the United States are shipped directly from its manufacturing and warehouse facilities located in Spanish Fork, Utah, as well as from its regional warehouses located in Georgia, Ohio and Texas. Its international operations maintain warehouse facilities with inventory to supply their customers. The Company's product lines by category includes; General health is a combination of assorted health products related to blood sugar support, bone health, cellular health, cognitive function, essential oils, joint health, mood, sexual health, sleep, sports and energy, and vision; Immunity line has been designed to offer products that support and strengthen the human immune system; Cardiovascular line has been designed to offer products that combine a variety of superior heart health ingredients to give the cardiovascular system optimum support; Disgestive line has been designed to offer products that regulate intestinal and digestive functions in support of the human digestive system; Personal care products for external use, including oils and lotions, aloe vera gel, herbal shampoo, herbal skin treatment, toothpaste and skin cleanser; and Weight manageme
» More Articles for NATR

Headlines

Articles On GuruFocus.com
Insider - no debt Mar 18 2013 
Nature's Sunshine CEO Resigns and Director Buys 365,000 Shares Mar 12 2013 
comment on NATR Nov 13 2012 
Is Nature’s Sunshine Breaking Through the Clouds? Mar 28 2012 

More From Other Websites
NATURES SUNSHINE PRODUCTS INC Financials Aug 21 2015
Prescott Group Capital Management’s Top Picks For Q3 Aug 13 2015
10-Q for Nature's Sunshine Products, Inc. Aug 12 2015
Nu Skin Enterprises, Inc. Earnings Analysis: By the Numbers Q2*, 2015 Aug 12 2015
NATURES SUNSHINE PRODUCTS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 11 2015
NATURES SUNSHINE PRODUCTS INC Files SEC form 10-Q, Quarterly Report Aug 10 2015
Nature's Sunshine posts 2Q profit Aug 10 2015
Nature's Sunshine posts 2Q profit Aug 10 2015
Nature's Sunshine Products Reports Second Quarter 2015 Financial Results Aug 10 2015
Nu Skin Enterprises, Inc.: Gathering momentum, can it sustain its performance? Aug 10 2015
Breakthrough Technologies Could Revolutionize CBD and Omega Delivery Systems Aug 10 2015
Q2 2015 Natures Sunshine Products Inc Earnings Release - 4:00 pm ET Aug 10 2015
Nature's Sunshine Products to Announce Second Quarter 2015 Financial Results and to Host Conference... Jul 27 2015
Is The Time Right To Buy Nature’s Sunshine Prod. (NATR)? Wynnefield Buying More On Macroeconomic... Jun 18 2015
Nature's Sunshine Chairman and CEO Joins Board of Directors for the Direct Selling Education... Jun 15 2015
Nature's Sunshine Honored as a Top Company by Direct Selling Association Jun 12 2015
Is Nature's Sunshine Products an Incredible Value Stock? 3 Reasons Why NATR Will Be Tough to Beat -... Jun 11 2015
NATURES SUNSHINE PRODUCTS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... May 15 2015
NATURES SUNSHINE PRODUCTS INC Files SEC form 10-Q, Quarterly Report May 11 2015
NATURES SUNSHINE PRODUCTS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK